Chris Sampson summarises a review on the cost-effectiveness of mental health workplace interventions, which presents up-to-date evidence on the different things that employers can do to help those in their workforce affected by mental health problems or substance misuse.[read the full story...]
Smoking cessation for people with severe mental illness? “Oh yes they can!” SCIMITAR+
David Shiers and Peter Byrne summarise the new SCIMITAR+ trial out today in The Lancet Psychiatry, which evaluates a bespoke smoking cessation intervention for people with severe mental illness.[read the full story...]
Have the EAGLES landed? Safety of varenicline, bupropion and NRT in smokers with and without mental illnesses
Paul Christiansen presents the results of the EAGLES RCT into the neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patches in smokers with and without psychiatric disorders.[read the full story...]
Can pharmacotherapy help smokers with severe mental disorders?
Andrew Jones reports on an ecological pragmatic clinical trial, which suggests that it is feasible to support smoking cessation in people with severe mental disorders such as bipolar disorder and schizophrenia.[read the full story...]
Pharmacotherapy for smoking cessation in severe mental illness
Andrew Jones reports on a recent systematic review and network meta-analysis of the efficacy and tolerability of pharmacotherapy for smoking cessation in severe mental illness, which finds a promising but low quality result for bupropion and varenicline.[read the full story...]
Nicotine patches, Varenicline and combination NRT: as good/bad as each other?
Paul Christiansen considers the findings of a recent RCT, which evaluates the effects of nicotine patches versus varenicline versus combination nicotine replacement therapy on smoking cessation at 26 weeks.[read the full story...]
Smoking and chronic mental illness: what’s the best way to quit or cut down?
Meg Fluharty considers the findings of a BMJ State of the Art review, which looks at the evidence for smoking cessation in people with chronic mental illness such as schizophrenia, unipolar depression, bipolar depression, anxiety disorders and PTSD.[read the full story...]
Varenicline is not associated with an increased risk of suicide or criminal behaviour
Abi Rose summarises a recent cohort study, which concludes that the smoking cessation drug varenicline is not associated with increased risk of suicidal or criminal behaviour, and association with psychiatric disorders are likely due to other factors.[read the full story...]
Promoting smoking cessation in people with schizophrenia
Meg Fluharty summarises a recent clinical overview of smoking cessation in people with severe mental illness, which provides useful practical advice to clinicians who are trying to help service users with schizophrenia, psychosis and other conditions to quit smoking[read the full story...]
Varenicline supports smoking reduction and smoking cessation, according to RCT
Paul Christiansen highlights an RCT of varenicline on smoking cessation through smoking reduction, which suggests that varenicline may be an effective treatment for smokers who wish to gradually reduce their cigarette consumption.[read the full story...]